However, when vorapaxar, the first PAR1 antagonist to receive U.S. Food & Drug Administration (FDA) approval, was found to cause bleeding complications in patients with peripheral artery disease [31], the focus began to shift to PAR4. Here, F2R is linked to peripheral arterial disease.